Tevogen Bio HoldingsTVGN
TVGN
About: Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Employees: 17
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
30% more funds holding
Funds holding: 27 [Q2] → 35 (+8) [Q3]
0.1% less ownership
Funds ownership: 3.41% [Q2] → 3.31% (-0.1%) [Q3]
28% less capital invested
Capital invested by funds: $2.9M [Q2] → $2.08M (-$820K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for TVGN.
Financial journalist opinion
Based on 7 articles about TVGN published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio.
Positive
Seeking Alpha
3 days ago
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound
Initiated a small position in Tevogen Bio Holdings Inc. due to a promising pipeline and favorable seasonal patterns, despite only one Wall Street analyst covering it. Tevogen Bio develops T-cell therapies for infectious diseases, cancers, and neurological disorders, with TVGN 489 completing Phase 1 trials for Long COVID and COVID-19. The stock has experienced significant price fluctuations, with lows likely due to tax loss selling and potential upside from the Santa Claus Rally and January effect.
Neutral
GlobeNewsWire
3 days ago
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
GlobeNewsWire
1 week ago
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.
Neutral
GlobeNewsWire
2 weeks ago
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, CEO of Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, Victor Sordillo PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month.
Neutral
GlobeNewsWire
3 weeks ago
Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy
WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities.
Neutral
GlobeNewsWire
4 weeks ago
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics.
Neutral
GlobeNewsWire
1 month ago
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
Neutral
GlobeNewsWire
1 month ago
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen's success would not be possible without its passionate team united by a common vision.
Neutral
GlobeNewsWire
1 month ago
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen's success would not be possible without its passionate team united by a common vision.
Charts implemented using Lightweight Charts™